Nasdaq IPOs

Gores Holdings V, the fifth blank check company formed by The Gores Group, filed on Monday with the SEC to raise up to $400 million in an initial public offering. The Beverly Hills, CA-based company plans to raise $400 million by offering 40 million units at $10. Each unit consis

Pershing Square Tontine Holdings, a blank check company formed by Bill Ackman of Pershing Square targeting "Mature Unicorns," is expected to price this week. For access to exact trade dates, screening capabilities, and other features, sign up for a free trial of IPO Pro. The New

ACell, which makes surgical soft tissue implants for wounds and hernia repair, postponed its IPO on Monday. It had filed to raise $75 million by offering 5 million shares at a price range of $14 to $16. The Columbia, MD-based company was founded in 1999 and booked $100 million in

Jamf Holding, which provides software for enterprises to remotely deploy Apple devices, raised the proposed deal size for its upcoming IPO on Monday. The Minneapolis, MN-based company now plans to raise $352 million by offering 16 million shares (16% insider) at a price range of

iTeos Therapeutics, a Phase 1/2 immuno-oncology biotech developing therapies for various cancers, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $151 million by offering 8.9 million shares at a price range of $16 to $18. At the midpoint of t

Inozyme Pharma, a preclinical biotech developing therapies for diseases of abnormal mineralization, announced terms for its IPO on Monday. The Boston, MA-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16. At the midpoint of the p

Vertex, which provides comprehensive tax software for businesses, announced terms for its IPO on Monday. The King of Prussia, PA-based company plans to raise $317 million by offering 21.2 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Vertex

Annexon, a Phase 1 biotech developing therapies for complement-mediated disorders, announced terms for its IPO on Monday. The South San Francisco, CA-based company plans to raise $150 million by offering 10 million shares at a price range of $14 to $16. At the midpoint of the pro

Nurix Therapeutics, a preclinical biotech developing small molecule therapies for cancer, announced terms for its IPO on Monday. The San Francisco, CA-based company plans to raise $150 million by offering 8.8 million shares at a price range of $16 to $18. At the midpoint of the p

Updated Monday, 7/20. Following a flurry of launches on Monday (and one postponement, ACell), seven IPOs and at least two SPACs plan to raise over $5.0 billion in the week ahead, led by Jamf Holding (JAMF). The IPO market is on a hot streak, and the IPO pipeline is filling u

Four IPOs and one SPAC plan to raise $663 million in the week ahead, led by Jamf Holding (JAMF). The IPO market is on a hot streak, and the IPO pipeline is filling up as filing activity remains high. Several companies could join the IPO calendar in the coming week, including lead

Eight IPOs and six SPACs entered public markets this past week, led by nCino (NCNO), which soared 195% in the biggest first-day pop for a US tech company in nearly 20 years. Cloud banking software provider nCino (NCNO) upsized and priced above the upwardly revised range to raise

Yucaipa Acquisition, a blank check company formed by private equity firm The Yucaipa Companies, filed on Friday with the SEC to raise up to $300 million in an initial public offering. The Los Angeles, CA-based company plans to raise $300 million by offering 30 million units at $1

Processa Pharmaceuticals, which is developing an analog therapy for necrotic skin disease, announced terms for its IPO on Friday. The Hanover, MD-based company plans to raise $20 million by offering 2.5 million shares at a price range of $7 to $9. At the midpoint of the proposed

BowX Acquisition, a blank check company formed by Bow Capital Management to acquire a TMT business, filed on Friday with the SEC to raise up to $350 million in an initial public offering. The Menlo Park, CA-based company plans to raise $350 million by offering 35 million units at

Freeline Therapeutics, a Phase 1/2 biotech developing gene therapies for rare diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering. The company's lead candidate, FLT180a, an investigational gene therapy medicinal product candidate for t

Checkmate Pharmaceuticals, a clinical stage immuno-oncology biotech developing therapies for solid tumors, filed on Friday with the SEC to raise up to $75 million in an initial public offering. The company's sole candidate, CMP-001, is a differentiated Toll-like re

Holicity, a blank check company focused on acquiring a TMT business, filed on Friday with the SEC to raise up to $250 million in an initial public offering. The Kirkland, WA-based company plans to raise $250 million by offering 25 million units at a price of $10. Each unit consis

Health Sciences Acquisitions 2, the second blank check company formed by RTW Investments to acquire a biopharma or medtech business, filed on Friday with the SEC to raise up to $125 million in an initial public offering. The New York, NY-based company plans to raise $125 million

NetSTREIT, a diversified retail REIT focused on the central United States, filed on Friday with the SEC to raise up to $100 million in an initial public offering. NetSTREIT's portfolio includes 163 single-tenant retail net leased properties spanning 34 states and its tenants incl